التفاصيل البيبلوغرافية
| العنوان: |
Medical Management for Fracture Prevention in Children with Osteogenesis Imperfecta. |
| المؤلفون: |
Arundel, Paul1 (AUTHOR), Bishop, Nick2 (AUTHOR) n.j.bishop@sheffield.ac.uk |
| المصدر: |
Calcified Tissue International. Dec2024, Vol. 115 Issue 6, p812-827. 16p. |
| مصطلحات موضوعية: |
*OSTEOGENESIS imperfecta, *STEM cell treatment, *MESENCHYMAL stem cells, *TREATMENT of fractures, *CLINICAL trials |
| مستخلص: |
There are no licensed treatments for children with osteogenesis imperfecta. Children currently receive off-label treatment with bisphosphonates, without any consistent approach to dose, drug or route of administration. Meta-analyses suggest that anti-fracture efficacy of such interventions is equivocal. New therapies are undergoing clinical trials, and it is likely that one or more will receive marketing authorisation within the next three to five years. The long-term outcome from such interventions will need to be studied carefully well beyond the period over which the clinical trials are conducted, and a consistent approach to the collection of data in this regard will be needed as a major collaborative effort. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |